Kosmas Macha

Dr. Kosmas Macha


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2016 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
PDF file
KMKosmas Macha
Kosmas Macha
BVBastian Volbers
Bastian Volbers
TBTobias Bobinger
Tobias Bobinger
NKNatalia Kurka
Natalia Kurka
LBLorenz Breuer
Lorenz Breuer
MKMartin Köhrmann
Martin Köhrmann

4 September 2019 in Cerebrovascular Diseases
Verified
Journal Article
Closed access
PDF file
AMArmin Marsch
Armin Marsch
KMKosmas Macha
Kosmas Macha
GSGabriela Siedler
Gabriela Siedler
LBLorenz Breuer
Lorenz Breuer
ESErwin F. Strasser
Erwin F. Strasser
BKBernd Kallmünzer
Bernd Kallmünzer
Introduction: The management of acute ischemic stroke in patients on direct oral anticoagulants (DOACs) is challenging. However, the substance-specific plasma level could guide treatment decisions on recanalization therapies. We present a plasma-level-based protocol for emergency treatment of stroke patients on oral anticoagulants. Bleeding complications and clinical outcome for patients on DOACs are reported and compared to patients on vitamin K antagonists (VKAs). Methods: In patients with acute ischemic stroke and suspected use of DOACs within 48 h prior to hospital admission, plasma levels were measured using the calibrated Xa-activity (apixaban, edoxaban, rivaroxaban) or the Hemoclot®-assay (dabigatran). Levels 100 ng/mL excluded patients from recombinant tissue plasminogen activator use. For patients on VKAs, the cutoff was set at international normalized ratio of 1.7. Endovascular thrombectomy of a large vessel occlusion was performed independently from coagulation testing. Consecutive patients were included in an observational registry. Results: Five hundred and twenty-two patients (261 on VKAs and 261 on DOACs) were included. Thirty patients (11.5%) on VKAs and 24 (9.2%) on DOACs received thrombolysis, followed by mechanical thrombectomy in 10 and 14 patients, respectively. Seventeen patients in each group received thrombectomy only. Symptomatic intracranial hemorrhage associated with thrombolysis occurred in 1 patient on VKA (3.3%) and 1 on DOAC (4.2%; p = 0.872). The turnaround time of specific assays did not show a significant delay in comparison to standard coagulation parameters. Conclusion: DOAC plasma levels could support decisions on emergency treatment of ischemic stroke. Systemic thrombolysis below suggested thresholds appears preliminary feasible and safe without an excess in bleeding complications.

1 January 2017 in The Veterinary Journal
Verified
Journal Article
Closed access
EZEric Zini
Eric Zini
IPI. Padrutt
I. Padrutt
KMKosmas Macha
Kosmas Macha
ARA. Riederer
A. Riederer
MPM. Pesaresi
M. Pesaresi
CRC.E. Reusch
C.E. Reusch

10 July 2021 in Neuroradiology
Verified
Journal Article
Open access
PDF file
KFKilian Fröhlich
Kilian Fröhlich
GSGabriela Siedler
Gabriela Siedler
SSSvenja Stoll
Svenja Stoll
KMKosmas Macha
Kosmas Macha
TKThomas M Kinfe
Thomas M Kinfe
MKMichael Knott
Michael Knott
Purpose: Endovascular therapy (EVT) of large-vessel occlusion in acute ischemic stroke (AIS) may be performed in general anesthesia (GA) or conscious sedation (CS). We intended to determine the contribution of ischemic cerebral lesion sites on the physician’s decision between GA and CS using voxel-based lesion symptom mapping (VLSM). Methods: In a prospective local database, we sought patients with documented AIS and EVT. Age, stroke severity, lesion volume, vigilance, and aphasia scores were compared between EVT patients with GA and CS. The ischemic lesions were analyzed on CT or MRI scans and transformed into stereotaxic space. We determined the lesion overlap and assessed whether GA or CS is associated with specific cerebral lesion sites using the voxel-wise Liebermeister test. Results: One hundred seventy-nine patients with AIS and EVT were included in the analysis. The VLSM analysis yielded associations between GA and ischemic lesions in the left hemispheric middle cerebral artery territory and posterior circulation areas. Stroke severity and lesion volume were significantly higher in the GA group. The prevalence of aphasia and aphasia severity was significantly higher and parameters of vigilance lower in the GA group. Conclusions: The VLSM analysis showed associations between GA and ischemic lesions in the left hemispheric middle cerebral artery territory and posterior circulation areas including the thalamus that are known to cause neurologic deficits, such as aphasia or compromised vigilance, in AIS-patients with EVT. Our data suggest that higher disability, clinical impairment due to neurological deficits like aphasia, or reduced alertness of affected patients may influence the physician’s decision on using GA in EVT.

5 August 2024 in Cerebrovascular Diseases
Verified
Journal Article
Closed access
PDF file
KMKosmas Macha
Kosmas Macha
JSJochen A. Sembill
Jochen A. Sembill
IMIris Muehlen
Iris Muehlen
TETobias Engelhorn
Tobias Engelhorn
ADArnd Doerfler
Arnd Doerfler
BKBernd Kallmünzer
Bernd Kallmünzer
Introduction: IV thrombolysis (IVT) is established in the unknown or extended time window based on multimodal imaging. Further, increasing evidence exists regarding IVT in patients on oral anticoagulation including direct oral anticoagulants (DOACs). However, data on IVT in ischemic stroke patients on oral anticoagulation with unknown time of stroke onset are sparse. Methods: This study bases on the longitudinal cohort study Stroke Research Consortium in Northern Bavaria (STAMINA; ClinicalTrials.gov Identifier: NCT04357899). Acute ischemic stroke patients treated with IVT in the unknown or extended time window from January 2015 to December 2019 were included. Patient selection was based on multimodal CT or MRI. Patients on oral anticoagulation (vitamin-K antagonist [VKA] or DOAC within 48 h) were eligible for IVT based on INR measurement (VKA) or plasma levels (DOAC) according to an institutional protocol. Primary outcomes were the incidence of any and symptomatic intracranial hemorrhage. Results: Of 170 ischemic stroke patients treated with IVT in the unknown or extended time window, 151 had no oral anticoagulation at stroke onset and 19 were on oral anticoagulation (6 on VKA and 13 on DOAC). The risk of symptomatic ICH according to ECASS II criteria was similar between the patients with and without oral anticoagulation (1 [5.3%] vs. 4 [2.7%], p = 0.453). After adjustment for confounding factors, pre-medication with oral anticoagulation was not associated with symptomatic ICH (aOR 1.02 [0.09–11.02], p = 0.988). Conclusion: IVT for ischemic stroke with unknown onset appeared safe in selected patients on oral anticoagulation with both DOAC and VKA.

1 April 2023 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
KMKosmas Macha
Kosmas Macha
SSStefan Schwab
Stefan Schwab
Decompressive hemicraniectomy (DHC) is the most effective intervention to treat the space-occupying effect of malignant cerebral infarction. Therefore, it is recommended by international guidelines to improve survival and potentially neurological outcome in selected patients with malignant middle-cerebral-artery (MCA) infarction.[1] In several studies, timing was identified as a relevant factor for the treatment effect of hemicraniectomy in patients with malignant cerebral infarction.[2] [3] Later, the randomized HAMLET trial[4] confirmed this finding, showing reduction of case fatality and poor outcome in patients treated within 48 hours of stroke onset but no effect on functional outcome in patients with treatment delayed up to 96 hours. Consequently, the pooled analysis of the randomized trials DECIMAL,[5] DESTINY,[6] and HAMLET[4] included only patients treated within 48 hours after stroke onset regardless of symptoms suggesting transtentorial herniation. In this large analysis of randomized patients (n = 93), all < 60 years old with severe stroke (NIHSS > 16), decompressive surgery led to higher rates of survival with mRS ≤ 4 (75 versus 24%; pooled absolute risk reduction 51%; 95% confidence interval [CI]: 34–69)), survival with mRS ≤ 3 (43 versus 21%; 23% [5–41]) and survival irrespective of functional outcome (78 versus 29%; 50% [33–67]). These results translate into impressive numbers needed to treat of 2 for survival with mRS ≤ 4, 4 for survival with mRS ≤ 3 and 2 for survival irrespective of functional outcome.[7] The DESTINY II trial revealed effectiveness of decompressive hemicraniectomy in patients > 60 years old for survival with mRS ≤ 4, indicating nonsevere disability (38 versus 18%; OR 2.91 [95%CI: 1.06–7.49]; p = 0.04).[8] In this issue of Arquivos de Neuro-Psiquiatria, Rodrigues et al.[9] present a study of 43 malignant MCA stroke patients treated with decompressive hemicraniectomy in a Brazilian tertiary hospital. The authors investigated the time course of hemispheric cerebral volume after decompressive hemicraniectomy using hemispheric volumetric measurements of all computed tomography scans (CT scans) performed during inpatient stay before and after DHC. In the study cohort, decompressive hemicraniectomy was performed 41.88 (Standard deviation 29.32) hours after stroke onset. The peak of the hemisphere volume was reached at day 7 (168.84 [95%CI: 142.08–195.59] hours) after the ischemic event. However, the steepest increase in hemisphere volume was demonstrated in the early phase after stroke onset and ∼ 28% of patients showed ipsilateral mydriasis before DHC. This highlights the importance of timely selection of malignant cerebral infarction patients requiring and potentially benefiting from decompressive hemicraniectomy. Advanced cerebral imaging could be supportive for this selection process. In an analysis of the DESTINY registry including 140 malignant middle-cerebral-artery infarction patients treated with decompressive hemicraniectomy and available semiautomatic quantification of infarction, an association of infarct volume with outcome could be demonstrated. In multivariable logistic regression, beside age and stroke severity, infarct size before hemicraniectomy was an independent predictor of unfavorable outcome (OR 1.27 for 10 ml increase [95%CI: 1.12–1.44]; p < 0.001). Additionally, the authors calculated an infarction volume threshold for unfavorable outcome with high specificity (94% for the overall cohort and 92% in younger patients [≤ 60 years old]) as > 258 ml before hemicraniectomy.[10] Furthermore, beside the proper selection of malignant cerebral infarction patients with potential to benefit from decompressive hemicraniectomy, quality of the neuro-surgical procedure is crucial for the treatment effect. In an interdisciplinary neurological-neurosurgical study including 60 malignant MCA infarction patients treated with DHC, the incidence of hemicraniectomy-associated parenchymal hemorrhages and hemicraniectomy-associated infarcts was 41.6 and 28.4%, respectively.[11] Small operative bone defects were associated with hemicraniectomy-related bleeding, leading to a significantly increased risk for mortality in these patients (survival rate 55 versus 80%; p < 0.05). The authors therefore suggested a bone deficit of at least 12 cm and additional duraplasty, as suboptimal hemicraniectomy might reduce the positive treatment effect and adversely affect functional outcome and mortality. The late occurrence of the peak hemisphere volume in the study by Rodriguez et al. points at the importance of postsurgical monitoring of the decompressive effect of the hemicraniectomy. Besides neuro-radiological cerebral imaging, bedside examinations by palpation of the hemicraniectomy area, automated pupillometry and midline shift monitoring using (transcranial) ultrasound could play an important role here and should be performed frequently in DHC patients. Here again, timely detection of requirement for and initiation of additional (rescue) intracranial pressure treatments as osmotic therapy or hypothermia in selected patients may be relevant for the patients' clinical course.[12] Even though broader availability of mechanical thrombectomy for large vessel occlusion acute ischemic stroke may reduce the incidence of malignant infarctions,[13] timing is the most important part in the management of patients with incipient malignant MCA- stroke. KM: conceptualization, writing – original draft; SS: conceptualization, writing – original draft, writing – review and editing. Received: 21 March 2023 Accepted: 22 March 2023 Article published online: 09 May 2023 © 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and...